US20020065319A1 - Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid - Google Patents
Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid Download PDFInfo
- Publication number
- US20020065319A1 US20020065319A1 US09/956,509 US95650901A US2002065319A1 US 20020065319 A1 US20020065319 A1 US 20020065319A1 US 95650901 A US95650901 A US 95650901A US 2002065319 A1 US2002065319 A1 US 2002065319A1
- Authority
- US
- United States
- Prior art keywords
- epa
- acid
- treatment
- pharmaceutical preparation
- efas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the invention relates to fatty acid treatment in schizophrenia.
- stearidonic acid (18:4 n-3), is as effective in inhibiting PLA2 as is EPA.
- EPA and SA are 20- and 18- carbon fatty acids which have in fact been shown to inhibit the activity of phospholipase A, (Finnen, Biochem Soc. Trans 1991; 19:915).
- DHA is A 22-carbon fatty acid which like other 22-carbon acids does not inhibit phospholipase. This may offer an explanation for the differences between EPA and DHA since there is evidence for overactivity of phospholipase A 2 in schizophrenia.
- stearidonic acid will be effective in treating schizophrenia and the other disorders and we include its use for that purpose alone or with EPA.
Abstract
A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present.
Description
- The invention relates to fatty acid treatment in schizophrenia.
- The essential fatty acids and their conversions in the body are shown in the following table.
n-6 EFAs n-3 EFAs 18:2n-6 18:3n-3 Linoleic acid (LA) α-linolenic acid (ALA) ↓ δ-6-desaturase ↓ 18:3n-6 18:4n-3 γ-Linolenic acid (GLA) Stearidonic acid. (SA) ↓ elongation ↓ 20:3n-6 20:4n-3 Dihomo-γ-linolenic acid Eicosatetraenoic acid (DGLA) ↓ ↓ δ-5-desaturase 20:5n-3 20:4n-6 Eicosapentaenoic acid (EPA) Arachidonic acid (AA) ↓ ↓ elongation 22:5n-3 22:4n-6 ↓ Adrenic acid (AdrA) 22-6n-3 ↓ δ-4-desaturase Docosahexaenoic acid (DHA) 22:5n-6 - The acids, which in nature are of the all - cis configuration, are systematically named as derivatives of the corresponding octadecanoic, eicosanoic or docosanoic acids, e.g. LA z,z-octadeca - 9,12 - dienoic acid or DHA z,z,z,z,z,z - docosa- 4,7,10,13,16,19 - hexaenoic acid, but numerical designations based on the number of carbon atoms, the number of centres of unsaturation and the number of carbon atoms from the end of the chain to where the unsaturation begins, such as, correspondingly, 18:2 n-6 or22:6 n-3, are convenient. Initials, e.g. EPA, and shortened forms of the name e.g. eicosapentaenoic acid, are used as trivial names in some instances.
- In previous patent applications EPA-0347856 and EPA-0599576 we have drawn attention to the action of various essential fatty acids in schizophrenia and have claimed the use of these fatty acids in treatment. We have particularly drawn attention to the low red cell levels of arachidonic acid (AA) and docosahexaenoic acid (DHA) and to the use of these fat acids.
- Present Work
- We have now unexpectedly found that one particular essential fatty acid which was previously accorded only a minor role is in fact particularly effective in treatment. This is eicosapentaenoic acid (EPA; 20:5n-3) which is present in the brain in only small amounts compared to AA and DHA. However, in a trial of treatment we have found that EPA is exceptionally effective in treatment of schizophrenia. Particularly effective are preparations comprising EPA in amounts of more than 20% of the total fatty acids present (preferably the total unsaturated fatty acids present), preferably more than 40% and very preferably more than 70%.
- Studies of the use of omega-3 essential fatty acids in treatment, using a mixture of DHA and EPA, have previously shown modestly beneficial effects (Mellor et al, Human Psychopharmacology 11:39-46, 1996). The preparation used contained 18% of EPA and 12% of DHA and so far as this disclosure goes the therapeutic effects could have been caused by either component or both. An analysis of the relationship between fatty acid change and schizophrenia symptoms showed that a rise in the total omega-3 content of red cell membranes was associated with a fall in schizophrenic symptoms.
- We therefore decided to try to determine the relative importance of EPA and DHA in schizophrenia. A study was carried out with 30 schizophrenia patients, most of whom had both positive and negative symptoms as shown by the positive and negative symptom scale (PANSS) and also had some evidence of tardive dyskinesia as shown by the abnormal involuntary movements scale (AIMS) Patients were randomly assigned on a double blind basis to treatment with 20 ml of a placebo emulsion, 20 ml of a 40% emulsion providing 8 g of oil containing approximately 2.0 g of EPA and 0.4 g of DHA per day (‘EPA group’), and 20 ml of an emulsion providing approximately 2.3 g of DHA and 0.5 g of EPA per day (‘DHA group’) in 8 g of oil. Patients were scored at baseline and at the end of 12 weeks of treatment. In the placebo group, 9 patients were unchanged or deteriorated on the PANSS and AIMS scores and one improved. In the DHA group, seven patients were unchanged or deteriorated and three patients improved. In contrast, in the EPA group one patient was unchanged but nine patients showed improvement. The improvement was seen in both the negative and positive symptom scores and in the AIMS score. There was therefore a broad spectrum improvement in all aspects of the schizophrenia syndrome. The DHA group was not significantly different from placebo whereas the EPA group was significantly better than both the DHA group and the placebo group (p<0.02 in both cases).
- It is therefore possible to conclude that the main therapeutic effect of treatment with EFAs is attributable to the effect of EPA. The other EFAs may contribute to some degree but there can be no doubt that EPA is primarily responsible for the positive effects of treatment with omega-3 EFA preparations. We concluded that EPA should also be effective in other psychiatric disorders such as Alzheimer's disease and repression since low levels of n-3 fatty acids nave been shown in the blood and/or the brain of patients with these disorders also Two patients with severe depression not responsive to the usual anti-depressants were therefore treated with the EPA formulation as used in the schizophrenia trial. Within 4 weeks both had shown remarkable improvement in their symptoms.
- While we cannot be certain of the mechanism by which EPA is working, one possibility is that it is inhibiting the enzyme, phospholipase A2. There is considerable evidence that phospholipase (PL) A2 activity is elevated in schizophrenia (Horrobin et al, Schizophrenia Research 1994; 13: 195-207). Compounds which safely inhibit PLA might therefore be expected to have a therapeutic effect. In in vitro studies of the effects of fatty acids on PLA2 activity we have found that EPA is a potent inhibitor, whereas the relatively similar fatty acid, DHA is not. This might explain why DHA did not prove effective in the clinical studies.
- We have further found that another n-3 fatty acid, stearidonic acid (18:4 n-3), is as effective in inhibiting PLA2 as is EPA. EPA and SA are 20- and 18- carbon fatty acids which have in fact been shown to inhibit the activity of phospholipase A, (Finnen, Biochem Soc. Trans 1991; 19:915). In contrast, DHA is A 22-carbon fatty acid which like other 22-carbon acids does not inhibit phospholipase. This may offer an explanation for the differences between EPA and DHA since there is evidence for overactivity of phospholipase A2 in schizophrenia. We therefore propose that stearidonic acid will be effective in treating schizophrenia and the other disorders and we include its use for that purpose alone or with EPA.
- The n-6 EFAs such as linoleic acid, gammalinolenic acid (GLA) dihomogammalinolenic acid (DGLA) and arachidonic acid (AA) are important in brain structure. GLA can be metabolised to DGLA and AA. We therefore tried to see whether the addition of an oil containing linoleic acid and GLA would be beneficial in two individuals who had responded to EPA. In fact their condition appeared to be less good with addition of the n-6 EFAs. It is therefore better to treat with EPA preparations in which the levels of n-6 EFAs are kept at a low level compared to the concentration of EPA. Either n-6 EFAs should be absent or if present at a ratio to EPA of not more than 1:3, preferably 1:4 or less.
- In any case to ensure that the effects secured are not countered the weight ratio of SA/EPA to any DHA present is desirably not less than 3:1 by weight and desirably 4:1 or more.
- The invention is set out in the claims herein but inter alia provides a pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present and wherein the weight ratio of SA/EPA to n-6 EFAs present is not less than 3:1 and is preferably 4:1 or more, or n-6 EFAs are absent. Corresponding methods of treatment, and methods of preparation of medicaments, wherein such oils as used, are also within the invention, as are corresponding treatments of depression or Alzheimer's disease or other dementias.
- The EPA can be provided in any appropriate way which will elevate the levels of EPA in the blood. Mono-, di-, and tri-glycerides, mono- or di-esters, salts, cholesterol esters, amides, phospholipids, free acids or any other appropriate form may be used to deliver the EPA. Mono or diesters of EPA as specified in previous applications where the present inventor is a co-inventor (PCT/GB96/01052 and 01053), published respectively as WO96/34855 and WO96/34846 are particularly convenient forms in which the EPA may be administered. The EPA, may be derived from fish or marine mammal oils, microbial oils or even from total chemical synthesis. The EPA dose used may range from 10 mg to 100 g/day, preferably 100 mg to 20 g/day and very preferably from 500 mg to 10 g/day. Oral, enteral, parenteral, topical, or any other appropriate route of administration may be used. Stearidonic acid may be provided in similar doses and in similar ways, alone or with the EPA.
- The study described above illustrates treatment according to the invention but examples of suitable formulations are as follows:
- 1. Soft gelatine capsules, each containing 200 mg of EPA in the form of one of the following:
- a) An oil containing 22% EPA derived from marine or microbial sources.
- b) An oil containing 56% EPA derived from marine or microbial sources.
- c) An oil containing 75% of EPA derived from marine or microbial sources.
- d) An oil containing 95% of EPA derived from marine, microbial or synthetic sources.
- e) EPA 1-3 propane diol diester.
- 2. Oils as in examples 1a to 1e but formulated as an emulsion for oral administration. The emulsion may contain 5 to 50% of the oil emulsified with emulsifying agents known to these skilled in the art including natural, synthetic and semi-synthetic agents such as phospholipids and galactolipids, the latter for example as described in PCT SE95/00115 published as WO95/20943 .
- 3. Emulsions as in 2 but sterilised and appropriately formulated for intravenous administration.
- 4. Oils as in examples 1a to 1e, sterilised and formulated for intramuscular or sub-cutaneous injection.
- 5. Oils as in examples 1a to 1e formulated for topical administration using patch or other technologies known to those skilled in the art.
- 6-10 As Examples 1-5 except that stearidonic acid is used instead of EPA or in admixture with it e.g. half and half.
Claims (7)
1. A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia, using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present and wherein the weight ratio of SA/EPA to n-6 EFAs present is not less than 3:1 and is preferably 4:1 or more, or n-6 EFAs are absent.
2. A method of treating, or a method of preparation of a medicament for treating, schizophrenia and/or tardive dyskinesia whereby EPA and/or SA is provided in the form of an oil containing more than 20% of said acid(s), preferably more than 40% and very preferably more than 70% by weight of the total (preferably total unsaturated) fatty acids present and wherein the weight ratio of SA/EPA to n-6 EFAs present is not less than 3:1 and is preferably 4:1 or more, or n-6 EFAs are absent.
3. A pharmaceutical preparation according to claim 1 , or method according to claim 2 , wherein the weight ratio of SA/EPA to any DHA present is not less than 3:1 and is preferably 4:1 or more.
4. A pharmaceutical preparation according to claim 1 or 3 or method according to claim 2 or 3 but for the treatment of depression.
5. A pharmaceutical preparation according to claim 1 or 3 or method according to claim 2 or 3 but for the treatment of Alzheimer's disease or other dementias.
6. Pharmaceutical preparation or medicament prepared as above which is suited to, or a method of treatment as above which employs, administration of 10 mg to 100 g, preferably 100 mg to 20 g, very preferably 500 mg to 10 g, EPA and/or SA daily.
7. Use of EPA and/or SA in the preparation of a-medicament for the treatment of schizophrenia and/or tardive dyskinesia, or depression, or Alzheimer's disease or other dementias, in the fox set out in claim 1 , for the administration of 10 mg to 100 g, preferably 100 mg to 20 g, very preferably 500 mg to 10 g, EPA and/or SA daily, with the weight ratio of SA/EPA to n-6 EFAs if present set out in claims 1 and 2 and desirably with the SA/EPA to DHA ratio set out in claim 3; and such treatment itself.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/956,509 US20020065319A1 (en) | 1996-10-11 | 2001-09-18 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
US10/428,020 US20040014810A1 (en) | 1996-10-11 | 2003-05-02 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9621294.9 | 1996-10-11 | ||
GBGB9621294.9A GB9621294D0 (en) | 1996-10-11 | 1996-10-11 | Fatty acid treatment |
GB9626062.5 | 1996-12-16 | ||
GBGB9626062.5A GB9626062D0 (en) | 1996-10-11 | 1996-12-16 | Fatty acid treatment |
US09/284,231 US6331568B1 (en) | 1996-10-11 | 1997-10-07 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
US09/956,509 US20020065319A1 (en) | 1996-10-11 | 2001-09-18 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/002738 Division WO1998016216A1 (en) | 1996-10-11 | 1997-10-07 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
US09/284,231 Division US6331568B1 (en) | 1996-10-11 | 1997-10-07 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/428,020 Continuation US20040014810A1 (en) | 1996-10-11 | 2003-05-02 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020065319A1 true US20020065319A1 (en) | 2002-05-30 |
Family
ID=26310221
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/284,231 Expired - Lifetime US6331568B1 (en) | 1996-10-11 | 1997-10-07 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
US09/956,509 Abandoned US20020065319A1 (en) | 1996-10-11 | 2001-09-18 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
US09/956,739 Expired - Fee Related US6624195B2 (en) | 1996-10-11 | 2001-09-18 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
US10/428,020 Abandoned US20040014810A1 (en) | 1996-10-11 | 2003-05-02 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
US10/617,184 Abandoned US20040048927A1 (en) | 1996-10-11 | 2003-07-11 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/284,231 Expired - Lifetime US6331568B1 (en) | 1996-10-11 | 1997-10-07 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/956,739 Expired - Fee Related US6624195B2 (en) | 1996-10-11 | 2001-09-18 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
US10/428,020 Abandoned US20040014810A1 (en) | 1996-10-11 | 2003-05-02 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
US10/617,184 Abandoned US20040048927A1 (en) | 1996-10-11 | 2003-07-11 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
Country Status (25)
Country | Link |
---|---|
US (5) | US6331568B1 (en) |
EP (1) | EP0956013B1 (en) |
JP (1) | JP4151853B2 (en) |
KR (2) | KR100657642B1 (en) |
CN (1) | CN1109543C (en) |
AT (1) | ATE236627T1 (en) |
AU (1) | AU731692C (en) |
BR (1) | BR9713479A (en) |
CA (1) | CA2268257C (en) |
CZ (1) | CZ293704B6 (en) |
DE (1) | DE69720787T2 (en) |
DK (1) | DK0956013T3 (en) |
ES (1) | ES2195175T3 (en) |
HK (1) | HK1020316A1 (en) |
ID (1) | ID21473A (en) |
IL (1) | IL129367A0 (en) |
IS (1) | IS2180B (en) |
NO (1) | NO326926B1 (en) |
NZ (1) | NZ334852A (en) |
PL (1) | PL190181B1 (en) |
PT (1) | PT956013E (en) |
SK (1) | SK285210B6 (en) |
TR (1) | TR199900786T2 (en) |
TW (1) | TW429145B (en) |
WO (1) | WO1998016216A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080090908A1 (en) * | 2003-05-14 | 2008-04-17 | Btg International Limited | Use of Triglyceride Oils Containing Gamma-Linolenic Acid Residues and Linoleic Acid Residues for the Treatment of Neurodegenerative Disease |
US20090023807A1 (en) * | 2005-03-02 | 2009-01-22 | Btg International Limited | Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters |
US20090036410A1 (en) * | 2004-11-25 | 2009-02-05 | Btg International Limited | Structured Phospholipids |
US20100113810A1 (en) * | 2003-08-18 | 2010-05-06 | Btg International Limited | Treatment of neurodegenerative conditions |
US20100297196A1 (en) * | 2005-03-02 | 2010-11-25 | Btg International Limited | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids |
US10808050B2 (en) * | 2014-10-24 | 2020-10-20 | Nof Corporation | Antibody-drug conjugate having cyclic benzylidene acetal linker |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100657642B1 (en) * | 1996-10-11 | 2006-12-19 | 스카리스타 리미티드 | Oil comprising eicosapentaenoic acid and/or stearidonic acid |
CA2311356C (en) * | 1998-01-28 | 2004-07-13 | Warner-Lambert Company | Method for treating alzheimer's disease |
US6107334A (en) | 1998-02-23 | 2000-08-22 | Wake Forest University | Dietary control of arachidonic acid metabolism |
US7138431B1 (en) | 1998-02-23 | 2006-11-21 | Wake Forest University | Dietary control of arachidonic acid metabolism |
FR2788437B1 (en) * | 1999-01-14 | 2006-08-11 | Inst Rech Biolog Sa | NEW USE OF PLANT AND ANIMAL PHOSPHOLIPIDS IN NUTRITIONAL THERAPEUTICS |
GB9901808D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Drugs for treatment of psychiatric and brain disorders |
AU2006201772B2 (en) * | 1999-01-27 | 2010-02-04 | Amarin Neuroscience Limited | Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
GB9904895D0 (en) * | 1999-03-03 | 1999-04-28 | Scarista Limited | Regulators of coenzyme-A-independent transacylase as psychotropic drugs |
ES2425114T3 (en) * | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-choline and uridine for the treatment of alcohol abuse |
IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
IL142536A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Carriers for therapeutic preparations for treatment of t-cell mediated diseases |
WO2002092779A2 (en) * | 2001-05-17 | 2002-11-21 | Pilot Therapeutics, Inc. | Method for enriching tissues in long chain polyunsaturated fatty acids |
ES2289153T7 (en) | 2001-11-08 | 2009-06-18 | Atrium Medical Corporation | INTRALUMINAL DEVICE WITH A COATING CONTAINING A THERAPEUTIC AGENT. |
NL1019368C2 (en) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparation for improving receptor performance. |
KR20050071565A (en) | 2002-10-10 | 2005-07-07 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents |
AU2004317087A1 (en) * | 2003-10-08 | 2005-09-22 | The Mclean Hospital Corporation | Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids |
WO2005034874A2 (en) * | 2003-10-08 | 2005-04-21 | The Mclean Hospital Corporation | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
AU2005208832A1 (en) * | 2004-01-19 | 2005-08-11 | Martek Biosciences Corporation | Reelin deficiency or dysfunction and methods related thereto |
ITMI20040069A1 (en) * | 2004-01-21 | 2004-04-21 | Tiberio Bruzzese | USE OF HIGH CONCENTRATION N-3 FATTY ACID COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM |
US7022713B2 (en) * | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
US20050266051A1 (en) * | 2004-05-27 | 2005-12-01 | The Procter & Gamble Company | Pet food compositions and methods |
US7737128B2 (en) * | 2004-06-10 | 2010-06-15 | The Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
EP1765364A4 (en) * | 2004-06-10 | 2010-09-22 | Mclean Hospital Corp | Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder |
EP1784199A4 (en) * | 2004-08-11 | 2010-06-23 | Mclean Hospital Corp | Compounds for the treatment of marihuana dependence, withdrawal, and usage |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US20060088596A1 (en) * | 2004-09-28 | 2006-04-27 | Atrium Medical Corporation | Solubilizing a drug for use in a coating |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US20090011116A1 (en) * | 2004-09-28 | 2009-01-08 | Atrium Medical Corporation | Reducing template with coating receptacle containing a medical device to be coated |
WO2006036970A2 (en) * | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Method of thickening a coating using a drug |
EP1811935B1 (en) | 2004-09-28 | 2016-03-30 | Atrium Medical Corporation | Heat cured gel and method of making |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
US7588931B2 (en) * | 2004-11-04 | 2009-09-15 | E. I. Du Pont De Nemours And Company | High arachidonic acid producing strains of Yarrowia lipolytica |
CN101102988B (en) * | 2004-11-19 | 2011-12-14 | 马泰克生物科学公司 | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
US20090318394A1 (en) * | 2004-11-19 | 2009-12-24 | Julie Nauroth | Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same |
US7893106B2 (en) * | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
KR20080027384A (en) * | 2005-07-08 | 2008-03-26 | 마텍 바이오싸이언스스 코포레이션 | Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
AU2006304590A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
JP2009520824A (en) * | 2005-12-20 | 2009-05-28 | セネストラ エルエルシー | Omega 3 fatty acid preparation |
EP1983977A4 (en) * | 2006-01-31 | 2011-11-30 | Martek Biosciences Corp | Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
EP2626091B1 (en) | 2006-11-06 | 2016-09-28 | Atrium Medical Corporation | Coated surgical mesh |
US20100130611A1 (en) * | 2006-12-20 | 2010-05-27 | Cenestra Llc | Omega 3 fatty acid formulations |
EP2120920A4 (en) * | 2007-02-20 | 2011-06-15 | Martek Biosciences Corp | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
EP2114155A4 (en) * | 2007-02-26 | 2014-04-16 | Yeda Res & Dev | Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses |
EP2117301A4 (en) * | 2007-02-26 | 2010-04-14 | Yeda Res & Dev | Use of long-chain alcohol derivatives for the treatment of alopecia areata |
CN101970638B (en) | 2007-10-03 | 2015-02-11 | 纳幕尔杜邦公司 | Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production |
US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
CA2704371A1 (en) * | 2007-11-01 | 2009-05-07 | Wake Forest University School Of Medicine | Compositions and methods for prevention and treatment of mammalian diseases |
WO2009086281A1 (en) * | 2007-12-21 | 2009-07-09 | Martek Biosciences Corporation | Method for preparation of oxylipins |
US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
US20110236476A1 (en) | 2008-09-02 | 2011-09-29 | Amarin Corporation Plc. | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
CA2773031C (en) | 2008-09-09 | 2021-03-02 | Orygen Youth Health Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
AU2015203289B2 (en) * | 2008-09-09 | 2017-03-16 | Orygen Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
US8060617B2 (en) * | 2008-12-19 | 2011-11-15 | Cisco Technology, Inc. | Reserving network resources during scheduling of meeting event |
KR20140007973A (en) | 2009-02-10 | 2014-01-20 | 아마린 파마, 인크. | Methods of treating hypertriglyceridemia |
GB0904300D0 (en) | 2009-03-12 | 2009-04-22 | Amarin Neuroscience Ltd | Essential fatty acid compounds |
NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
NZ627238A (en) | 2009-04-29 | 2016-02-26 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
MY172372A (en) | 2009-06-15 | 2019-11-21 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for lowering triglycerides |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
WO2011038122A1 (en) | 2009-09-23 | 2011-03-31 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
US8372465B2 (en) | 2010-02-17 | 2013-02-12 | Bunge Oils, Inc. | Oil compositions of stearidonic acid |
KR20130026428A (en) * | 2010-03-04 | 2013-03-13 | 아마린 파마, 인크. | Compositions and methods for treating and/or preventing cardiovascular disease |
EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
WO2012083034A1 (en) * | 2010-12-15 | 2012-06-21 | Louis Sanfilippo | Modulation of neurotrophic factors by omega-3 fatty acid formulations |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
EP2540292A1 (en) * | 2011-06-28 | 2013-01-02 | Nestec S.A. | DHA and EPA in the reduction of oxidative stress |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
EP2866801A4 (en) | 2012-06-29 | 2016-02-10 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10058552B2 (en) * | 2014-02-07 | 2018-08-28 | University Of Utah Research Foundation | Combination of creatine, an omega-3 fatty acid, and citicoline |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
ES2607715B1 (en) * | 2015-10-01 | 2018-01-17 | Solutex Na, Lcc | PROCESS FOR THE PREPARATION AND STABILIZATION OF EMULSIONS WITH OMEGA-3 THROUGH ISOMETRIC CRYSTAL NETWORKS OF CELLULOSE DERIVATIVES |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
KR102296068B1 (en) | 2018-09-24 | 2021-09-02 | 애머린 파마슈티칼스 아일랜드 리미티드 | Methods of Reducing the Risk of a Cardiovascular Event in a Subject |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1239587A (en) | 1983-10-24 | 1988-07-26 | David Rubin | Combined fatty acid composition for lowering blood cholestrol and triglyceride levels |
GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
GB8813766D0 (en) * | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
GB8906369D0 (en) * | 1989-03-20 | 1989-05-04 | Tisdale Michael J | Eicosapentaenoic acid |
CH678181A5 (en) * | 1989-05-22 | 1991-08-15 | Nestle Sa | |
GB9001121D0 (en) * | 1990-01-18 | 1990-03-21 | Efamol Holdings | Efa compositions and therapy |
ES2059880T3 (en) * | 1990-05-23 | 1994-11-16 | Nestle Sa | USE OF STEARIDONIC ACID FOR THE TREATMENT OF INFLAMMATORY DISEASES. |
JP3400466B2 (en) | 1991-10-28 | 2003-04-28 | 日本水産株式会社 | Method for producing high-purity eicosapentaenoic acid or ester thereof |
GB9224809D0 (en) | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
GB9519661D0 (en) * | 1995-09-27 | 1995-11-29 | Scotia Holdings Plc | Fatty acid treatment |
KR100657642B1 (en) * | 1996-10-11 | 2006-12-19 | 스카리스타 리미티드 | Oil comprising eicosapentaenoic acid and/or stearidonic acid |
US6590846B2 (en) * | 1999-05-21 | 2003-07-08 | Matsushita Electric Industrial Co., Ltd. | Recordable optical disk |
-
1997
- 1997-10-07 KR KR1019997003079A patent/KR100657642B1/en not_active IP Right Cessation
- 1997-10-07 US US09/284,231 patent/US6331568B1/en not_active Expired - Lifetime
- 1997-10-07 CA CA002268257A patent/CA2268257C/en not_active Expired - Fee Related
- 1997-10-07 TR TR1999/00786T patent/TR199900786T2/en unknown
- 1997-10-07 CZ CZ19991154A patent/CZ293704B6/en not_active IP Right Cessation
- 1997-10-07 BR BR9713479-1A patent/BR9713479A/en not_active Application Discontinuation
- 1997-10-07 AU AU45667/97A patent/AU731692C/en not_active Ceased
- 1997-10-07 JP JP51808698A patent/JP4151853B2/en not_active Expired - Fee Related
- 1997-10-07 DK DK97944022T patent/DK0956013T3/en active
- 1997-10-07 WO PCT/GB1997/002738 patent/WO1998016216A1/en not_active Application Discontinuation
- 1997-10-07 ES ES97944022T patent/ES2195175T3/en not_active Expired - Lifetime
- 1997-10-07 ID IDW990162A patent/ID21473A/en unknown
- 1997-10-07 CN CN97198908A patent/CN1109543C/en not_active Expired - Fee Related
- 1997-10-07 DE DE69720787T patent/DE69720787T2/en not_active Expired - Lifetime
- 1997-10-07 PL PL97333423A patent/PL190181B1/en not_active IP Right Cessation
- 1997-10-07 KR KR1020067009861A patent/KR20060061409A/en not_active Application Discontinuation
- 1997-10-07 AT AT97944022T patent/ATE236627T1/en active
- 1997-10-07 IL IL12936797A patent/IL129367A0/en active IP Right Grant
- 1997-10-07 NZ NZ334852A patent/NZ334852A/en not_active IP Right Cessation
- 1997-10-07 SK SK448-99A patent/SK285210B6/en not_active IP Right Cessation
- 1997-10-07 PT PT97944022T patent/PT956013E/en unknown
- 1997-10-07 EP EP97944022A patent/EP0956013B1/en not_active Expired - Lifetime
- 1997-10-09 TW TW086114830A patent/TW429145B/en not_active IP Right Cessation
-
1999
- 1999-03-30 IS IS5017A patent/IS2180B/en unknown
- 1999-04-06 NO NO19991635A patent/NO326926B1/en not_active IP Right Cessation
- 1999-11-26 HK HK99105486A patent/HK1020316A1/en not_active IP Right Cessation
-
2001
- 2001-09-18 US US09/956,509 patent/US20020065319A1/en not_active Abandoned
- 2001-09-18 US US09/956,739 patent/US6624195B2/en not_active Expired - Fee Related
-
2003
- 2003-05-02 US US10/428,020 patent/US20040014810A1/en not_active Abandoned
- 2003-07-11 US US10/617,184 patent/US20040048927A1/en not_active Abandoned
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080090908A1 (en) * | 2003-05-14 | 2008-04-17 | Btg International Limited | Use of Triglyceride Oils Containing Gamma-Linolenic Acid Residues and Linoleic Acid Residues for the Treatment of Neurodegenerative Disease |
US7935729B2 (en) | 2003-05-14 | 2011-05-03 | Btg International Limited | Use of triglyceride oils containing γ-linolenic acid residues and linoleic acid residues for the treatment of neurodegenerative disease |
US20110184063A1 (en) * | 2003-05-14 | 2011-07-28 | Btg International Limited | Treatment of neurodegenerative conditions |
US20100113810A1 (en) * | 2003-08-18 | 2010-05-06 | Btg International Limited | Treatment of neurodegenerative conditions |
US20100113595A1 (en) * | 2003-08-18 | 2010-05-06 | Btg International Limited | Treatment of neurodegenerative conditions |
US7964641B2 (en) | 2003-08-18 | 2011-06-21 | Btg International Limited | Treatment of neurodegenerative conditions |
US20090036410A1 (en) * | 2004-11-25 | 2009-02-05 | Btg International Limited | Structured Phospholipids |
US20090023807A1 (en) * | 2005-03-02 | 2009-01-22 | Btg International Limited | Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters |
US20100297196A1 (en) * | 2005-03-02 | 2010-11-25 | Btg International Limited | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids |
US8114903B2 (en) | 2005-03-02 | 2012-02-14 | Btg International Limited | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids |
US10808050B2 (en) * | 2014-10-24 | 2020-10-20 | Nof Corporation | Antibody-drug conjugate having cyclic benzylidene acetal linker |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6624195B2 (en) | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid | |
US5116624A (en) | Efa compositions and therapy | |
AU618814B2 (en) | Essential fatty acid compositions | |
RU2276975C2 (en) | Therapeutic combinations of fatty acids | |
CA2073913A1 (en) | Preparation of fatty acid medicaments | |
JPS62226923A (en) | Iron-containing composition and therapy for cancer | |
IL129367A (en) | Pharmaceutical preparations comprising an oil containing eicosapentaenoic acid and/or stearidonic acid for the treatment of psychiatric disorders and a novel stearidonic acid-containing oil therefor | |
MXPA99003365A (en) | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid | |
NZ239126A (en) | The use of essential fatty acids to treat schizophrenia and associated tardive dyskinesia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: SCARISTA LIMITED, ISLE OF MAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCOTIA HOLDINGS PLC;REEL/FRAME:014268/0968 Effective date: 20030214 |